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urham, North Carolina
The right dose of the right drug to the right person” is an
ften-stated goal of pharmacogenomics and personalized
edicine. Pharmacogenetics primarily uses genetic variants
o identify subgroups of patients that may respond differ-
ntly to a certain class of medications. Warfarin has become
n interesting and important case study for pharmacogenet-
cs. The drug has a narrow therapeutic index with high
nterindividual variability in dose response; the use of
enetic information improves the ability to predict warfarin
ose requirements (1). The ultimate goals of genotype-
uided warfarin therapy are to: 1) reduce the risk of major
leeding events by avoiding supratherapeutic international
ormalized ratio (INR) values; and 2) provide better pro-
ection from thrombosis by reducing subtherapeutic INR
alues during warfarin initiation. For over a decade,
See page 2804
ow investigators have reported that genetic variants in
YP2C9 and, more recently, VKORC1 alter warfarin dose
equirements (2) and have extended these data to laboratory
3) and clinical adverse events (4) during standard dose
arfarin initiation. Translating these observations into tools
hat physicians can use to improve health outcomes for
ndividual patients is challenging and requires establishing
vidence of improved outcomes: reduction in adverse events,
eduction in cost, or improvements in quality of life. The
ppropriate level of evidence required for a pharmacogenetic
est to be adopted into clinical practice, however, has not yet
een established. An evidence-based review in 2008 found
hat CYP2C9 and VKORC1 variant testing to guide warfarin
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entures.osing had good analytic and clinical validity but also
oncluded that there was insufficient evidence to show a
eduction in serious bleeding events (5). Although the bulk
f evidence for genotype-guided warfarin therapy has been
erived from retrospective data, small (n 200 patients)
rospective studies have provided mixed results, with 1
tudy failing to find any benefit (6) when compared with
tandard warfarin therapy and another finding reductions in
leeding events (7). Although a prospective randomized
ontrolled trial is considered the evidentiary “gold standard,”
t has been criticized for genotype-guided warfarin therapy
ecause the trial setting itself may result in closer monitor-
ng than would be seen in the real world, an effect that may
bscure any potential benefits. Cost-effectiveness analyses of
genotype-guided strategy for warfarin have also been
nconclusive and suggest that cost savings are sensitive to the
ost of genetic testing, overall effectiveness, and the indi-
idual patient’s risk of hemorrhage (8). Thus, although 50%
f the variance in warfarin dose requirements is accounted
or by CYP2C9 and VKORC1 variants along with clinical
nd demographic variables, prediction algorithms based on
hese factors (1,2) to tailor the initial warfarin dose are
eldom used because of the contradictory data and the lack
vidence to support coverage of the cost of genotyping by
nsurers.
In other cases of pharmacogenetic testing, there appear to
e different thresholds for adoption and coverage, thus
ighlighting the lack of uniform standards for evaluation.
his is not altogether surprising, because a test that limits
he use of an expensive (e.g., cetuximab) or potentially toxic
e.g., abacavir) medication to those most likely to benefit or
east likely to experience toxicity should be held to a
ifferent standard than a test that guides the methods of
nitiating therapy (e.g., warfarin). Genotyping colonic ade-
ocarcinomas for gain of function genetic variants in KRAS
o guide the use of cetuximab to those who benefit the most
s considered standard of care by most oncologists and is
overed by the Center for Medicare and Medicaid Services
CMS): a decision that was based on retrospective analyses
f samples collected in randomized clinical trials (9). How-
ver, testing for HLA-B*5701 prior to administering aba-
avir to avoid hypersensitivity reactions was only adopted
fter demonstration of efficacy in a prospective randomized
linical trial (10).
Pharmacogenetics-based warfarin therapy currently pre-
ents a conundrum to physicians, regulators, and payers. On
his backdrop, in this issue of the Journal Epstein et al. (11)
erformed a “single arm” prospective intervention study of
96 patients initiating warfarin therapy. Potential study
articipants were identified at the time when a warfarin
rescription was filled and then subsequently contacted for
nformed consent, genomic sample collection, genotyping,
nd reporting of CYP2C9 and VKORC1 genotypes to the
atient’s physician along with a basic interpretation of test
esults. The investigators chose as their control population a
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Warfarin Pharmacogenetic Testing June 22, 2010:2813–5istorical cohort of 2,688 age- and sex-matched patients
rawn from the same geographical areas and insurance
lans. The median time from warfarin initiation to provid-
ng genotype information was 32 days. The intervention
roup, compared with the historical controls, had 31% fewer
ospitalizations overall (adjusted hazard ratio: 0.69, 95%
onfidence interval: 0.58 to 0.82, p  0.001) and 28% fewer
ospitalizations for bleeding or thromboembolism (hazard
atio: 0.72, 95% confidence interval: 0.53 to 0.97, p  0.03)
uring the 6-month period following warfarin initiation. To
ccount for potential biases in temporal trends, the investi-
ators compared 2 external cohorts (contemporary vs. his-
orical) and found no difference in hospitalizations during
he 2 time periods.
Epstein et al. (11) should be commended for reporting
utcomes on the largest cohort of patients receiving
enotype-guided warfarin initiation in a real-world setting.
owever, the main limitation of this study is its use of a
istorical control group. This leaves open the possibility that
he benefits of genotype-guided warfarin therapy may be
xaggerated due to cofounding, either in the vigilance by the
reating physicians or the kinds of patients who agreed to
articipate. Although the investigators went to great lengths
multivariable adjustment, propensity scoring, matching) to
ccount for differences between groups, it is conceivable that
here is bias in the types of physicians that agreed to
articipate in the intervention and/or that factors differed
etween the intervention and the historical groups that were
ot measured or captured, such as patient education and
ocioeconomic status. Furthermore, it was unexpected that a
imilar reduction for all-cause versus thromboembolic/
emorrhagic hospitalization outcomes was observed, when
ne would have anticipated a preferential reduction for the
atter. This may reflect that the patients (or their treating
hysicians) were systematically different in the intervention
ersus historical cohorts in a way that confounds the primary
utcomes. This limitation could have easily been overcome
y randomly selecting a contemporary control population.
nother limitation was that the genotype information was
elivered at a median of 32 days after initiating warfarin
herapy. The investigators state that this intervention influ-
nced provider actions, as indicated by appropriate dose
djustments in the 3 weeks following genotyping that was
onsistent with individual patients’ genotypes. Although the
ata are consistent with this assertion, one cannot arrive at
his conclusion based on these data alone. The observed
ose changes may have occurred even without the genotype
nformation because INR measurements were being made
uring the first 32 days of warfarin therapy (before the
enotype information was delivered). In fact, INR values
btained during the first week of warfarin initiation have
een shown to be highly correlated with the final dose
equirements (12). Therefore, although this study has its
aws, the results suggest that there may be benefits of
enotype-guided warfarin therapy when implemented in the
real world” that include clinically meaningful reductions in fatient outcomes: namely hospitalizations due to bleeding
nd thromboembolism.
So what is the path forward for warfarin pharmacogenet-
cs? Two important, ongoing, National Heart, Lung, and
lood Institute–sponsored prospective clinical trials—the
OAG (Clarification of Optimal Anticoagulation Through
enetics) and the GIFT (Genetics Informatics Trial of
arfarin to Prevent Deep Venous Thrombosis) studies—
ill enroll 1,200 and 1,600 patients, respectively, and
ill prospectively test the hypothesis that genetically guided
herapy improves laboratory (COAG study) and thrombotic/
emorrhagic (GIFT study) outcomes. Both will be impor-
ant studies; however, results are not anticipated until 2011
t the earliest. Until then, we believe that additional
esearch should be performed that takes advantage of the
overage with evidence development (CED) status provided
or warfarin pharmacogenetic testing by CMS that will
eimburse the cost of genetic testing if a Medicare benefi-
iary is enrolled in a prospective, randomized, outcomes
tudy. We implore other payers to follow suit with CED for
his and other genetic tests where a pathway to evidence
eneration needs to be blazed. In addition, a standard
osing algorithm (13) should be used during warfarin
nitiation in prospective randomized trials and observational
tudies, and we encourage more comparative effectiveness
esearch that uses these tools versus the standard of care.
Beyond the research agenda for pharmacogenetics, there
re policy issues that need to be concurrently addressed for
he path to adoption to be a clear one. Health systems and
ayers need to be prepared and aligned to implement
harmacogenetics-based testing. This will require: 1) phy-
ician education of genetic testing; 2) reimbursement of
enetic tests by payers; and 3) infrastructure to perform and
o report in a timely manner genetic testing by health care
elivery systems. With better alignment of the stakeholders,
hen novel genetic tests become available, they can be
ntroduced into the health care markets. Comparative ef-
ectiveness research can provide the initial signals of efficacy
hat would lay the groundwork for coverage decisions or
andomized controlled trials, if necessary. Evaluation of
harmacogenetic testing could be treated in a similar fash-
on as have novel imaging modalities such as positron
mission tomography (PET) scanning for initial diagno-
is and staging of malignancies. Beginning in 2006, PET
as covered by CMS under the CED program for certain
alignancies with the stipulation that patients be placed
n the National Oncologic PET Registry, and on the
asis of this registry data, CMS expanded PET coverage
n 2009 (14).
Defining the evidentiary paths for pharmacogenetic test-
ng is important as we look to the future of pharmacoge-
etics in clinical practice. Through the National Heart,
ung, and Blood Institute’s commitment, the COAG and
IFT studies will soon provide high-level evidence on
arfarin pharmacogenetics. However, will this be the pathor other pharmacogenetic tests? It is difficult to imagine
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arker combination, particularly for approved drugs such as
arfarin where there will be few incentives and resources for
onducting these studies. Recently, for example, clopidogrel
eceived a “black box” warning stating that carriers of
YP2C19 loss of function alleles do not receive its full
enefits. Alternative thienopyridines, such as prasugrel,
ight be prescribed for carriers to mitigate the increased
isk of laboratory (15) and clinical (16) outcomes conferred
y these alleles, although prospective genotyping has not
een tested in a clinical trial. Applying CED status to
YP2C19 variant testing within a registry, as was done for
ET scanning, might encourage the use of genetic testing
nd generate evidence that might be sufficient to justify
enotype-guided thienopyridine therapy. Having the appro-
riate resources and infrastructure to implement genotype-
uided therapies will further enable the type of clinical
esearch reported by Epstein et al. (11) to generate efficacy
ignals for statins (17–20) and other important classes of
ardiovascular drugs, such as oral thrombin inhibitors, that
ave promising pharmacogenetic applications. For example,
abigatran, if approved, could be considered a superior,
hough more expensive, oral anticoagulant that might be
eserved for difficult-to-manage carriers of CYP2C9 or
KORC1 variants while noncarriers are given warfarin. This
ramework could easily be explored in substudies of ran-
omized controlled trials, if genomic samples were stored,
nd through observational data if genetic testing and inter-
retation were widely available. Such a strategy may ulti-
ately require a randomized trial; however, until we lay the
roundwork for developing the appropriate evidentiary path
or pharmacogenetic testing, personalized medicine will
emain an often-cited goal that remains on the research
orizon without any tangible benefits for patients.
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